Karyopharm Therapeutics Ownership | Who Owns Karyopharm Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Karyopharm Therapeutics Ownership Summary


Karyopharm Therapeutics is owned by 81.50% institutional investors, 4.46% insiders, and 14.04% retail investors. Ra capital management is the largest institutional shareholder, holding 17.53% of KPTI shares. Vanguard Morn Total Stk Mkt Idx Investor is the top mutual fund, with 2.99% of its assets in Karyopharm Therapeutics shares.

KPTI Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockKaryopharm Therapeutics81.50%4.46%14.04%
SectorHealthcare Stocks 50.59%12.40%37.01%
IndustryBiotech Stocks 49.10%12.14%38.76%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management1.92M17.53%$10.68M
Adage capital partners gp1.81M16.52%$10.06M
T. rowe price investment management1.54M14.10%$8.59M
Goldman sachs group947.58K8.67%$5.28M
Catalio capital management, lp897.71K8.21%$5.00M
Vanguard group559.62K6.46%$4.12M
Affinity asset advisors500.00K4.57%$2.79M
Avidity partners management lp463.74K4.24%$3.85M
Soleus capital management440.00K4.02%$2.45M
Millennium management420.57K3.85%$2.34M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Catalio capital management, lp897.71K1.04%$5.00M
Avidity partners management lp463.74K0.87%$3.85M
Acorn capital advisors287.83K0.46%$1.60M
Birchview capital, lp419.83K0.23%$283.93K
Boxer capital management302.54K0.22%$1.69M
Affinity asset advisors500.00K0.14%$2.79M
Ra capital management1.92M0.11%$10.68M
Soleus capital management440.00K0.10%$2.45M
Eversept partners, lp276.17K0.08%$1.54M
Silverback asset management65.00K0.05%$362.05K

Top Buyers

HolderShares% AssetsChange
Ra capital management1.92M0.11%1.92M
Adage capital partners gp1.81M0.02%1.39M
Goldman sachs group947.58K0.00%947.58K
Catalio capital management, lp897.71K1.04%754.73K
Millennium management420.57K0.00%420.57K

Top Sellers

HolderShares% AssetsChange
Blackrock4.17M0.00%-5.28M
Commodore capital lp---1.95M
Deutsche bank ag\---1.27M
Kennedy capital management---1.20M
Alphacentric advisors---1.13M

New Positions

HolderShares% AssetsChangeValue
Ra capital management1.92M0.11%1.92M$10.68M
Millennium management420.57K0.00%420.57K$2.34M
Acorn capital advisors287.83K0.46%287.83K$1.60M
Eversept partners, lp276.17K0.08%276.17K$1.54M
Brevan howard capital management lp212.37K0.01%212.37K$1.18M

Sold Out

HolderChange
Pittenger & anderson-3.00
Zurcher kantonalbank (zurich cantonalbank)-6.00
Advisory services network-12.00
Farther finance advisors-13.00
Nelson, van denburg & campbell wealth management group-22.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202665-14.47%8,911,554-5.86%812.94%40-13.04%6-
Dec 31, 202512-79.31%752,172-74.49%80.74%5-72.22%--100.00%
Sep 30, 202518-62.50%552,924-86.33%60.29%5-79.17%3-50.00%
Jun 30, 2025524.00%4,384,528-15.32%50281.78%27575.00%7-83.33%
Mar 31, 202551-45.74%5,312,129-91.28%40.17%4-88.89%4386.96%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Morn Total Stk Mkt Idx Investor677.73K2.99%168.60K
Vanguard Total Stock Mkt Idx Inv677.73K2.99%168.60K
Vanguard MStar Total Stk Mkt Idx Invest677.73K2.99%-
Vanguard US Total Market Shares ETF3.42M2.71%-1.00
iShares Russell 2000 ETF479.64K2.12%-8.54K
T. Rowe Price Small-Cap Value435.07K1.92%-100.40K
Vanguard Explorer Inv133.88K1.55%-
T. Rowe Price U.S. SC Value Eq Tr-D312.41K1.38%-298.64K
Vanguard Institutional Extnd Mkt Idx Tr263.08K1.16%-
AlphaCentric LifeSci Healthcare I1.13M0.90%-

Recent Insider Transactions


DateNameRoleActivityValue
Jul 28, 2026Poulton Stuart EVP, Chief Development OfficerSell$1.34K
May 14, 2026Poulton Stuart EVP, Chief Development OfficerSell$3.83K
May 14, 2026Rangwala Reshma EVP & Chief Medical OfficerSell$3.88K
May 14, 2026Cheng Sohanya Roshan EVP & Chief Commercial OfficerSell$3.08K
May 14, 2026Abate Kristin Chief Accounting OfficerSell$503.50

Insider Transactions Trends


DateBuySell
2026 Q3-1
2026 Q2-7
2026 Q1-9
2025 Q4-1
2025 Q3-9

KPTI Ownership FAQ


Who Owns Karyopharm Therapeutics?

Karyopharm Therapeutics shareholders are primarily institutional investors at 81.50%, followed by 4.46% insiders and 14.04% retail investors. The average institutional ownership in Karyopharm Therapeutics's industry, Biotech Stocks , is 49.10%, which Karyopharm Therapeutics exceeds.

Who owns the most shares of Karyopharm Therapeutics?

Karyopharm Therapeutics’s largest shareholders are Ra capital management (1.92M shares, 17.53%), Adage capital partners gp (1.81M shares, 16.52%), and T. rowe price investment management (1.54M shares, 14.10%). Together, they hold 48.16% of Karyopharm Therapeutics’s total shares outstanding.

Does Blackrock own Karyopharm Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Karyopharm Therapeutics.

Who is Karyopharm Therapeutics’s biggest shareholder by percentage of total assets invested?

Catalio capital management, lp is Karyopharm Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.04% of its assets in 897.71K Karyopharm Therapeutics shares, valued at 5M$.

Who is the top mutual fund holder of Karyopharm Therapeutics shares?

Vanguard Morn Total Stk Mkt Idx Investor is the top mutual fund holder of Karyopharm Therapeutics shares, with 2.99% of its total shares outstanding invested in 677.73K Karyopharm Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools